Sep 24, 2019
Drug candidates often fail in the clinic for two reasons: they lack efficacy or possess an adverse toxicity profile. These failures can come at a high cost, especially when drug candidates have already progressed along the development pipeline to clinical trial.
Advances in three-dimensional (3D) cell culture systems are helping address the above challenges and improve the likelihood of success for pipeline assets. From disease modelling and validation of novel targets to screening for safety and efficacy, 3D cell cultures offer the exciting potential for the development of novel medicines and increased productivity.
This episode describes the benefit of 3D cell culture on the drug discovery workflow, with a focus on lead optimisation in which compounds are assessed for their potential metabolic liability and off-target toxicities. The powerful combination of human-induced pluripotent stem cells (HiPSCs) and 3D cell culture systems are also highlighted.
Original article by Dr Richard M. Eglen, Dr Feng Li and Dr Tony Frutos
If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: